Eikon Therapeutics's earnings have been declining at an average annual rate of -9.7%, while the Biotechs industry saw earnings growing at 34.1% annually.
How Eikon Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
NasdaqGS:EIKN Revenue, expenses and earnings (USD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
30 Jun 26
0
-322
68
270
31 Mar 26
0
-342
70
261
31 Dec 25
0
-334
67
247
30 Sep 25
0
-319
63
236
31 Dec 24
0
-244
56
205
Quality Earnings: EIKN is currently unprofitable.
Growing Profit Margin: EIKN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if EIKN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare EIKN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EIKN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (64.6%).
Return on Equity
High ROE: EIKN has a negative Return on Equity (-69.06%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/21 04:52
End of Day Share Price
2026/08/21 00:00
Earnings
2026/06/30
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Eikon Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.